Related references
Note: Only part of the references are listed.Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases
B. Pariente et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
The Role of Thiopurines in Reducing the Need for Surgical Resection in Crohn's Disease: A Systematic Review and Meta-Analysis
Sukhdev Chatu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Postoperative Therapy With Infliximab Prevents Long-term Crohn's Disease Recurrence
Miguel Regueiro et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
Simon P. L. Travis et al.
GUT (2014)
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
Pieter Dewint et al.
GUT (2014)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet et al.
GUT (2014)
INFLIXIMAB OR CICLOSPORIN: PATIENTS' TREATMENT PREFERENCES AND THE IMPACT OF ULCERATIVE COLITIS (UC) ON THEIR LIVES
A. Seagrove et al.
GUT (2014)
Rescue Therapy with Cyclosporine or Infliximab is not Associated with an Increased Risk for Postoperative Complications in Patients Hospitalized for Severe Steroid-refractory Ulcerative Colitis
Ryan Nelson et al.
INFLAMMATORY BOWEL DISEASES (2014)
Genetic Polymorphisms in Metabolizing Enzymes Modifying the Association Between Smoking and Inflammatory Bowel Diseases
Ashwin N. Ananthakrishnan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Delving into disability in Crohn's disease: Dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease
D. R. van Langenberg et al.
JOURNAL OF CROHNS & COLITIS (2014)
Optimising post-operative Crohn's disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study
M. A. Kamm et al.
JOURNAL OF CROHNS & COLITIS (2014)
Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at risk?
Robert V. Bryant et al.
JOURNAL OF CROHNS & COLITIS (2014)
Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial
R. Khanna et al.
JOURNAL OF CROHNS & COLITIS (2014)
Objectively measured muscle fatigue in Crohn's disease: Correlation with self-reported fatigue and associated factors for clinical application
D. R. van Langenberg et al.
JOURNAL OF CROHNS & COLITIS (2014)
Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life
Christopher S. J. Probert et al.
JOURNAL OF CROHNS & COLITIS (2014)
Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect
Gareth C. Parkes et al.
JOURNAL OF CROHNS & COLITIS (2014)
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2014)
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
R. Khanna et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis
B. Flourie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study
M. Watanabe et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis
N. A. Kennedy et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
R. Panaccione et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Systematic review: body composition in adults with inflammatory bowel disease
R. V. Bryant et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial
Edoardo Savarino et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Postoperative recurrence of Crohn's disease: impact of endoscopic monitoring and treatment step-up
P. De Cruz et al.
COLORECTAL DISEASE (2013)
Moving towards disease modification in inflammatory bowel disease therapy
Patrick B. Allen et al.
CURRENT OPINION IN GASTROENTEROLOGY (2013)
Definition and evaluation of mucosal healing in clinical practice
Silvia Mazzuoli et al.
DIGESTIVE AND LIVER DISEASE (2013)
Management of Postoperative Recurrence of Crohn's Disease
Anja U. van Lent et al.
DIGESTIVE DISEASES (2013)
Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial
Jacques Cosnes et al.
GASTROENTEROLOGY (2013)
Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
Julian Panes et al.
GASTROENTEROLOGY (2013)
Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study
Nabeel Khan et al.
GASTROENTEROLOGY (2013)
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
Simon P. L. Travis et al.
GASTROENTEROLOGY (2013)
Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome
Dan Knights et al.
GUT (2013)
Evolving Definitions of Remission in Crohn's Disease
Remo Panaccione et al.
INFLAMMATORY BOWEL DISEASES (2013)
P-145 Welcome 54-week Open-label Extension
Brian Feagan et al.
INFLAMMATORY BOWEL DISEASES (2013)
Mucosal Healing in Crohn's Disease: A Systematic Review
Peter De Cruz et al.
INFLAMMATORY BOWEL DISEASES (2013)
Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients
Maria Chaparro et al.
INFLAMMATORY BOWEL DISEASES (2013)
Risk Factors for Osteoporosis in Crohn's Disease: Infliximab, Corticosteroids, Body Mass Index, and Age of Onset
Neville Azzopardi et al.
INFLAMMATORY BOWEL DISEASES (2013)
Methotrexate in Ulcerative Colitis: A Nationwide Retrospective Cohort from the Veterans Affairs Health Care System
Nabeel Khan et al.
INFLAMMATORY BOWEL DISEASES (2013)
Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Disease
Christian P. Selinger et al.
INFLAMMATORY BOWEL DISEASES (2013)
Long-Term Mesalamine Maintenance in Ulcerative Colitis: Which is More Important? Adherence or Daily Dose
Nabeel Khan et al.
INFLAMMATORY BOWEL DISEASES (2013)
Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation
Sjoerd F. Bakker et al.
JOURNAL OF CROHNS & COLITIS (2013)
Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease
A.J. Walsh et al.
Journal of Crohns & Colitis (2013)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Histological healing in inflammatory bowel disease: A still unfulfilled promise
Vincenzo Villanacci et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system
N. Khan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
Laurent Peyrin-Biroulet et al.
GUT (2012)
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Simon P. L. Travis et al.
GUT (2012)
Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
Corey A. Siegel
GUT (2012)
Mucosal healing in inflammatory bowel diseases: a systematic review
Markus F. Neurath et al.
GUT (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis
Brian G. Feagan et al.
INFLAMMATORY BOWEL DISEASES (2012)
Ulcerative colitis as a progressive disease: The forgotten evidence
Joana Torres et al.
INFLAMMATORY BOWEL DISEASES (2012)
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis
Haruhiko Ogata et al.
INFLAMMATORY BOWEL DISEASES (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
David Laharie et al.
LANCET (2012)
Review article: explaining risks of inflammatory bowel disease therapy to patients
C. A. Siegel
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Review article: defining remission in ulcerative colitis
S. P. L. Travis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Systematic review: the role of tacrolimus in the management of Crohn's disease
K. McSharry et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Khurram J. Khan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
David S. Kotlyar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis
Mark Lamet
DIGESTIVE DISEASES AND SCIENCES (2011)
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean Frederic Colombel et al.
GASTROENTEROLOGY (2011)
Conventional Medical Management of Inflammatory Bowel Disease
Daniel Burger et al.
GASTROENTEROLOGY (2011)
Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers
Simon Travis et al.
GUT (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Guidelines for the management of inflammatory bowel disease in adults
Craig Mowat et al.
GUT (2011)
Assessment and Management of Low Bone Density in Inflammatory Bowel Disease and Performance of Professional Society Guidelines
Jason P. Etzel et al.
INFLAMMATORY BOWEL DISEASES (2011)
Development of the Crohn's Disease Digestive Damage Score, the Lemann Score
Benjamin Pariente et al.
INFLAMMATORY BOWEL DISEASES (2011)
Pediatric Modification of the Montreal Classification for Inflammatory Bowel Disease: The Paris Classification
Arie Levine et al.
INFLAMMATORY BOWEL DISEASES (2011)
Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status
Robert V. Bryant et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
Vitamin D Deficiency in Patients With Inflammatory Bowel Disease: Association With Disease Activity and Quality of Life
Alex Ulitsky et al.
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION (2011)
Genetics and pathogenesis of inflammatory bowel disease
Bernard Khor et al.
NATURE (2011)
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
S. Lichtiger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
Asher Kornbluth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial
Toshifumi Ohkusa et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis
Gert Van Assche et al.
JOURNAL OF CROHNS & COLITIS (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
The pattern and outcome of acute severe colitis
Lotte C. Dinesen et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine mercaptopurine
M. Wahed et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Delayed-Release Oral Mesalamine 4.8 g/day (800-mg Tablet) Is Effective for Patients With Moderately Active Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2009)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Adalimumab for the treatment of fistulas in patients with Crohn's disease
J-F Colombel et al.
GUT (2009)
Ciprofloxacin or Metronidazole for the Treatment of Perianal Fistulas in Patients with Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Kelvin T. Thia et al.
INFLAMMATORY BOWEL DISEASES (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Rectal tacrolimus in the treatment of resistant ulcerative proctitis
I. C. Lawrance et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Mesalamine Foam Enema Versus Mesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis
Antoine Cortot et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Predictors of severe Crohn's disease
Catherine Loly et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
Stephen B. Hanauer et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis:: a combined analysis of two randomized, double-blind, placebo-controlled trials
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study
Giovanni C. Actis et al.
BMC GASTROENTEROLOGY (2007)
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
Miles P. Sparrow et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression
Dan Turner et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
H. Ogata et al.
GUT (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Predictors of Crohn's disease
L Beaugerie et al.
GASTROENTEROLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
S Ardizzone et al.
GUT (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial
SB Hanauer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
P Marteau et al.
GUT (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Oral Pentasa in the Treatment of Active Crohn's Disease: A Meta-Analysis of Double-Blind, Placebo-Controlled Trials
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
J Arts et al.
INFLAMMATORY BOWEL DISEASES (2004)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
P Rutgeerts et al.
GASTROENTEROLOGY (2004)
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study
RL West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
How effective are the usual treatments for ulcerative colitis?
JR Bebb et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study
TP Van Staa et al.
GASTROENTEROLOGY (2004)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
Long-term Treatment of Rectovaginal Fistulas in Crohn's Disease: Response to Infliximab in the ACCENT II Study
Bruce E. Sands et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
G Van Assche et al.
GASTROENTEROLOGY (2003)
Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients
FN Aberra et al.
GASTROENTEROLOGY (2003)
The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
WJ Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Medication Nonadherence and the outcomes of patients with quiescent ulcerative colitis
S Kane et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines
RAJ Ransford et al.
GUT (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
AG Fraser et al.
GUT (2002)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
BE Sands et al.
INFLAMMATORY BOWEL DISEASES (2001)
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
